Alector

Historical price data

Founded in 2013 and publicly traded on Nasdaq, Alector is on a mission to slow and prevent neurodegenerative diseases by harnessing insights from human genetics, immunology, and neuroscience. The company has built a robust pipeline of potential first- and best-in-class candidates, with its lead program, latozinemab (AL001), in a pivotal Phase 3 trial for frontotemporal dementia and AL101 in Phase 2 for Alzheimer's disease via a major collaboration with GSK. Alector's strategy combines internal R&D with high-value partnerships, supported by a seasoned leadership team with deep expertise in drug discovery and development.

The Alector Brain Carrier (ABC) is a proprietary, versatile technology platform designed to transport therapeutic payloads (antibodies, enzymes, siRNAs) across the blood-brain barrier, enabling targeted delivery to the central nervous system.

12 drugs in pipeline, 2 in Phase 3

Total raised: $454M

Alector faces competition from large pharma (Eli Lilly, Roche, Eisai/Biogen) developing amyloid and tau-targeting therapies for Alzheimer's, and biotechs like Denali in Parkinson's. Its primary differentiation lies in its immuno-neurology approach—modulating brain immune function rather than directly clearing proteins—and its ABC blood-brain barrier delivery platform, which may enable more effective targeting of disease pathways.